Retatrutide Side Effects: What the Clinical Trial Data Shows
Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in late-stage clinical trials for obesity and type 2 diabetes. It is not FDA-approved. The side-effect profile from phase 2 trials is dominated by gastrointestinal symptoms, nausea, vomiting, diarrhoea, similar to semaglutide and tirzepatide. Long-term safety is not yet established.
Retatrutide (Retatrutide) is investigational as a Triple GIP / GLP-1 / glucagon receptor agonist (investigational). Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin.
Key Takeaways
- Retatrutide is not FDA-approved, it is investigational. Any retatrutide outside a clinical trial is not a regulated medicine.
- Most common trial side effects: nausea, vomiting, diarrhoea, constipation, decreased appetite, typical of GLP-1-class agents.
- Glucagon receptor activation may raise heart rate and blood pressure modestly and affect liver glucose handling.
- Long-term safety, thyroid risk, and rare adverse events are not yet fully characterised, most data are from phase 2 trials.
- Compounded or gray-market retatrutide is not FDA-regulated and may have purity, potency, and sterility risks.
- If considering retatrutide, do so only within a clinical trial supervised by qualified investigators.
What is Retatrutide, and what is it used for?
Retatrutide is an investigational triple agonist activating GIP, GLP-1, and glucagon receptors. It is in clinical trials for obesity and type 2 diabetes. No FDA approval or marketed product is available as of this review.
| Property | Detail |
|---|---|
| Drug name | Retatrutide (investigational) |
| Drug class | Triple GIP / GLP-1 / glucagon receptor agonist |
| FDA approval status | Not approved, in clinical trials |
| Route | Subcutaneous injection, once weekly (in trials) |
| Common trial side effects | Nausea, vomiting, diarrhoea, constipation, decreased appetite |
| Mechanism-related considerations | Glucagon activation may raise heart rate, blood pressure, and affect liver glucose output |
| Marketed product available? | No |
What are the side effects of Retatrutide?
The FDA prescribing information for Retatrutide groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Retatrutide alongside other medications?
Check Retatrutide against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Retatrutide work, and why does that drive the side effects?
Retatrutide activates three incretin/metabolic receptors: GIP, GLP-1, and glucagon. The GLP-1 and GIP actions slow gastric emptying and suppress appetite (driving the GI side effects and weight loss); the glucagon component increases energy expenditure and hepatic glucose output but can raise heart rate and blood pressure. The triple agonism produced greater weight loss in phase 2 trials than dual or single agonists, but long-term safety remains under investigation.
Can you drink alcohol while taking Retatrutide?
No alcohol-retatrutide trials exist. Combining alcohol with any investigational drug outside a trial protocol is not advisable.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Retatrutide:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Retatrutide Side Effects
No. Retatrutide is investigational and in late-stage clinical trials. It is not yet FDA-approved, and any retatrutide available outside a clinical trial is not a regulated medicine.
In phase 2 trials, the most common side effects were gastrointestinal, nausea, vomiting, diarrhoea, constipation, decreased appetite, similar to semaglutide and tirzepatide. Heart rate and blood pressure changes have also been observed, attributed to glucagon receptor activation.
Retatrutide adds glucagon receptor activation to GIP/GLP-1, producing greater weight loss in phase 2 trials than tirzepatide. Direct head-to-head trials are limited. Long-term safety is less established.
Compounded retatrutide is not FDA-regulated. Purity, potency, and sterility are not guaranteed, and there is no validated clinical use protocol. Use outside a clinical trial is not recommended.
Eli Lilly is conducting phase 3 trials. Approval timelines depend on trial outcomes and regulatory review. As of this review, no FDA approval has been granted.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Retatrutide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.